Abstract: Provided are a pyrroloquinoline quinone glycine betaine salt and a crystalline form thereof. The pyrroloquinoline quinone glycine betaine salt has the advantages of high solubility, good stability, a simple preparation process and low solvent residue.

Abstract: A lighting apparatus includes a fixing bracket, a driver plate, a driver circuit, a driver container, a manual switch, a shielding cover, a cover plate and a light source. The fixing bracket has a first wall, a second wall and a third wall. The first wall and the third wall are connected on two sides of the second wall. The first wall has a door opening. The driver circuit is mounted on the driver plate. The driver container is fixed to the fixing bracket. The driver container has a driver opening facing to the first wall. The manual switch disposed on the driver plate. The manual switch has a switch pin to be moved for selecting a setting of the driver circuit. The shielding cover conceals the manual switch so that users do not touch the manual switch directly from outside of the lighting apparatus.

Abstract: Provided are a pyrroloquinoline quinone glycine betaine salt and a crystalline form thereof. The pyrroloquinoline quinone glycine betaine salt has the advantages of high solubility, good stability, a simple preparation process and low solvent residue.

Abstract: The invention discloses a form A of mesylate for nicotinamide derivatives and preparation method and application thereof, wherein the XRPD pattern of the form A of mesylate for nicotinamide derivatives has a diffraction peak at 2?=5.34, 10.341, 14.438, 15.841, 17.32, 18.301, 18.68, 19.005, 19.577, 20.26, 21.161, 21.859, 22.379, 23.04, 23.5, 24.177, 24.959, 25.881, 26.641, 27.18, 28.3, 28.999, 29.501, 31.96, 32.258, 33.999, 36.798, 37.38 and 41.297 with the error range of the 2? values being ±0.2. The form A of mesylate for nicotinamide derivatives provided by the present invention has excellent high-temperature stability, high-humidity stability and illumination stability, and it can be applied to drugs for treating advanced non-small cell lung cancers, gastric cancers, liver cancer or breast cancer. It has preferable bioavailability, and meanwhile the provided qualitative and quantitative information has great significance on further study of the efficacy of such solid drugs.

Abstract: The invention discloses a form A of mesylate for nicotinamide derivatives and preparation method and application thereof, wherein the XRPD pattern of the form A of mesylate for nicotinamide derivatives has a diffraction peak at 2?=5.34, 10.341, 14.438, 15.841, 17.32, 18.301, 18.68, 19.005, 19.577, 20.26, 21.161, 21.859, 22.379, 23.04, 23.5, 24.177, 24.959, 25.881, 26.641, 27.18, 28.3, 28.999, 29.501, 31.96, 32.258, 33.999, 36.798, 37.38 and 41.297 with the error range of the 2? values being ±0.2. The form A of mesylate for nicotinamide derivatives provided by the present invention has excellent high-temperature stability, high-humidity stability and illumination stability, and it can be applied to drugs for treating advanced non-small cell lung cancers, gastric cancers, liver cancer or breast cancer. It has preferable bioavailability, and meanwhile the provided qualitative and quantitative information has great significance on further study of the efficacy of such solid drugs.

Abstract: Provided are several types of ginsenoside polymorphic substances and a method for preparing same. In particular, new crystal form A, crystal form B, crystal form C, crystal form E, crystal form F, crystal form I, crystal form K, crystal form L, crystal form M, crystal form N, and crystal form O are involved.

Abstract: Provided are ginsenoside C-K polymorphic forms and a method for preparing same. The ginsenoside C-K polymorphic forms are crystal form D and crystal form H.

Abstract: Provided are several types of ginsenoside polymorphic substances and a method for preparing same. In particular, new crystal form A, crystal form B, crystal form C, crystal form E, crystal form F, crystal form I, crystal form K, crystal form L, crystal form M, crystal form N, and crystal form O are involved.

Abstract: Provided are ginsenoside C-K polymorphic forms and a method for preparing same. The ginsenoside C-K polymorphic forms are crystal form D and crystal form H.

Abstract: An amorphous asiatic tromethamine salt and the preparation method thereof. The method includes the steps of: (1) dissolving asiatic acid in an organic solvent; step (2) mixing with tromethamine; step (3) stirring and salifying the same, and then removing the organic solvent. The method for preparing the amorphous asiatic tromethamine salt is easy and effective, and the water solubility and bioavailability of the asiatic tromethamine salt thus obtained are greatly compared with the prior art.

Abstract: An amorphous asiatic tromethamine salt and the preparation method thereof. The method includes the steps of: (1) dissolving asiatic acid in an organic solvent; step (2) mixing with tromethamine; step (3) stirring and salifying the same, and then removing the organic solvent. The method for preparing the amorphous asiatic tromethamine salt is easy and effective, and the water solubility and bioavailability of the asiatic tromethamine salt thus obtained are greatly compared with the prior art.